Moberg focuses on Europe

European focus for Moberg Pharma – opens up for acquisitions

Following the disappointing US Phase III results, Moberg Pharma is now focusing on launching Terclara in Europe. The position in Sweden...

February 11
BioStock Intestor Pitch with Moberg Pharma

BioStock Investor Pitch: Moberg Pharma

After many years of work, Moberg Pharma has now reached the market with its nail fungus treatment. How has the over-the-counter drug Terclara...

June 12th, 2024
Anna Ljung, CEO of Moberg Pharma

Redemption in Moberg's TO 2 funds international Terclara launch

Sales of Moberg Pharma's drug against nail fungus are underway. Already in its first full month of launch, Terclara was the market leader in...

June 10th, 2024
Anna Ljung, CEO of Moberg Pharma

Can Moberg Pharma become a world leader?

The company that recently launched Teclara, an over-the-counter drug for nail fungus, has global plans. Now it is currently working on a solution...

June 4th, 2024
Anna Ljung, CEO of Moberg Pharma

Moberg's CEO on the launch of Terclara

Many have probably already seen the TV commercial for the nail fungus product Terclara. The Swedish launch has had a flying start, something Moberg...

20th of May 2024
Anna Ljung, CEO of Moberg Pharma, talks about the business

Moberg Pharma's CEO on launch plans and share issue

Moberg Pharma has already had several successful treatments for nail fungus on the market. Now they are on the way with their...

August 24
Moberg Pharma, BioStock Investor Pitch

BioStock Investor Pitch: Moberg Pharma

Specialist pharmaceutical company Moberg Pharma operates in the area of ​​nail fungus treatments where it has already launched several products.

August 22
Moberg Pharma is approaching market launch of MOB-015

Market launch next for Moberg Pharma

With fresh market approval for Sweden and Ireland behind it, Moberg Pharma is approaching perhaps the most important step yet...

August 18
Anna Ljung, CEO of Moberg Pharma

Moberg Pharma's CEO on the issue and launch of MOB-015

Moberg Pharma has achieved several successes with its treatments against nail fungus over the years. Now the company is about to...

August 16
Issuance brings Moberg Pharma's MOB-015 to market

Issuance brings Moberg Pharma's MOB-015 to market

Nasdaq company Moberg Pharma aims to repeat the success of Kerasal Nail and become a world leader in the treatment of nail fungus. MOB-015,...

19th of May 2022
Moberg Pharma's CEO on the nail fungus killer MOB-015

Moberg Pharma's CEO on the nail fungus killer MOB-015

Many associate the pharmaceutical company Moberg Pharma with the success of the nail fungus product Kerasal Nail, which was divested in 2019. Now the company aims to...

16th of May 2022

Innovation in focus at the BioStock Life Science Spring Summit 2021

Like last year, this year's flagship event, the Life Science Spring Summit, is being organized as a virtual two-day event. Tomorrow, Wednesday and Thursday...

25th of May 2021